Abstract
Although responses to EGFR tyrosine kinase inhibitors (EGFR-TKIs) are initially positive, 30%-40% of patients with EGFR-mutant tumors do not respond w......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
